SCHEMBL25344717

SCHEMBL25344717

CCOC(=O)c1cnn2c(Br)c(C)nc(Cl)c12

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.45
NPC1 O15118 5/20 0.45
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 8/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11617706 0.77 ALDH1A1 (0.44) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL11640645 0.77 ALDH1A1 (0.50) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL24075710 0.75 KDM4E (0.46) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL24075066 0.75 KDM4E (0.46) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL25343568 0.74 ALDH1A1 (0.50) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL31329788 0.74 RAB9A (0.45) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL24075086 0.74 KDM4E (0.45) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL21589205 0.74 RAB9A (0.47) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2
SCHEMBL25346064 0.74 PDXK (0.30) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL20265295 0.73 RAB9A (0.49) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORP (US) 2025-09-11 US disclosed
CN-119212994-A Pyrazolopyrazine compounds as SHP2 inhibitors 建新公司 2024-12-27 CN disclosed
EP-4448526-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2024-10-23 EP disclosed
EP-4227307-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Genzyme Corporation (US) 2023-08-16 EP disclosed
EP-4227307-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS Genzyme Corporation (US) 2023-08-16 EP disclosed
WO-2023114954-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS GENZYME CORPORATION (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282782-A1 PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS PTPN5, PTPN2, PTPRJ RAB9A 1560/4885NPC1 3344/4885KDM4E 1559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.